Mainz Biomed NV (NASDAQ:MYNZ) Sees Large Decrease in Short Interest

Mainz Biomed NV (NASDAQ:MYNZ) saw a large decrease in short interest during the month of February. As of February 13th, there was short interest totaling 246,769 shares, a decrease of 23.5% from the January 29th total of 322,531 shares. Based on an average trading volume of 245,630 shares, the short-interest ratio is presently 1.0 days. Currently, 2.7% of the company’s stock are sold short. Currently, 2.7% of the company’s stock are sold short. Based on an average trading volume of 245,630 shares, the short-interest ratio is presently 1.0 days.

Mainz Biomed Stock Up 8.8%

Shares of MYNZ stock traded up $0.07 during midday trading on Wednesday, reaching $0.91. 230,213 shares of the stock were exchanged, compared to its average volume of 615,351. Mainz Biomed has a 1 year low of $0.55 and a 1 year high of $5.62. The firm has a market cap of $8.24 million, a PE ratio of -0.01 and a beta of 0.31. The company has a current ratio of 0.52, a quick ratio of 0.43 and a debt-to-equity ratio of 0.44. The company’s 50 day moving average is $1.01 and its two-hundred day moving average is $1.29.

Wall Street Analyst Weigh In

MYNZ has been the subject of several research analyst reports. Wall Street Zen raised Mainz Biomed to a “hold” rating in a research report on Saturday, December 27th. Weiss Ratings reiterated a “sell (e)” rating on shares of Mainz Biomed in a research report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Hedge Funds Weigh In On Mainz Biomed

Institutional investors and hedge funds have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC increased its stake in Mainz Biomed by 200.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock worth $34,000 after buying an additional 20,000 shares in the last quarter. Cerity Partners LLC bought a new position in shares of Mainz Biomed during the 4th quarter valued at approximately $183,000. Finally, Armistice Capital LLC increased its position in Mainz Biomed by 45.0% during the second quarter. Armistice Capital LLC now owns 285,000 shares of the company’s stock valued at $402,000 after acquiring an additional 88,400 shares during the last quarter.

About Mainz Biomed

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.